Showing results (441-450 of 541) with videos related to

Sort By:
Pageof 55
Ebiomedicine|November 4, 2019
CD8+T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunctionFanny Lebossé, Cathrin Gudd, Enes Tunc, et al.
The Lancet. Infectious Diseases|December 9, 2014
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trialK Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, et al.
Clinics and Research in Hepatology and Gastroenterology|February 1, 2015
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC studyFrançois Bailly, Victor Virlogeux, Cécilie Dufour, et al.
Nature Medicine|February 7, 2017
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis BPaola Fisicaro, Valeria Barili, Barbara Montanini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 22, 2025
Simultaneous Activation of Beta-Oxidation and De Novo Lipogenesis in MASLD-HCC: A New ParadigmFatima Dahboul, Jihan Sun, Benjamin Buchard, et al.
Gut|December 28, 2019
Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meetingMatias A Avila, Jean-François Dufour, Alexander L Gerbes, et al.
Scientific Reports|March 31, 2018
Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytesJulie Lucifora, Marc Bonnin, Ludovic Aillot, et al.
Gut|April 12, 2012
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosisRoeland Zoutendijk, Jurrien G P Reijnders, Fabien Zoulim, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 28, 2017
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE StudyVictor de Lédinghen, Claire Laforest, Christophe Hézode, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 25, 2011
Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates)Piero L Almasio, Sergio Babudieri, Giorgio Barbarini, et al.
Pageof 55